journal article·2025-07-30

Ion-Gradient Driven Drug-Loading Liposomes for Codelivery of Shikonin/Regorafenib for Cancer Immunometabolic Therapy and Postoperative Intervention

Xinyue Shao, Taoxing Peng, Chenxiao Yang, Jie Zhu, Rui Wang, Lu Yang, Jiazhen Hou, Huiyuan Wang, Yongzhuo Huang

ACS Applied Materials & Interfaces· Volume 17· Issue 30
Publisher page

Abstract

Lactate emerges as a pivotal immunometabolite in tumor progression, orchestrating immunosuppression by polarizing tumor-associated macrophages (TAMs) toward pro-tumor M2 phenotypes and activating immunosuppressive cell populations. Targeting intratumoral lactate has emerged as a promising therapeutic strategy for tumors with poor immune responses. Shikonin (SHK) inhibited the lactate production of tumor cells by targeting pyruvate kinase M2 (PKM2). Regorafenib (REGO), an FDA-approved multikinase inhibitor, repolarized TAMs from M2-like to tumor-suppressive M1 phenotypes. To overcome their clinical limitations of off-targeting and systemic toxicity, a T12 peptide-modified liposome (T12-SR-LP) was constructed to encapsulate SHK and REGO through an ion-gradient method. T12-SR-LP exhibited a high total drug loading efficiency of 10.5%, attributed to copper ion-mediated coordination. Furthermore, the hydrogel with T12-SR-LP (T12-SR-LP@Gel) significantly suppressed tumor growth and recurrence compared to controls. This study highlighted T12-SR-LP as a promising strategy targeting both the metabolic and immune facets of the tumor microenvironment to combat "cold" tumors with poor immune activity.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Rd, Shanghai 201203, China

University of Chinese Academy of Sciences

School of Life Science and Technology

ShanghaiTech University

The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Provincial Key Laboratory for Precision Pathology and Intelligent Diagnosis, Postdoctoral Innovation Practice Base, The First Affiliated Hospital, Jiangxi Medical College

Nanchang University

Nanchang University College of Pharmacy, 461 Bayi Rd, Nanchang 330006, China

School of Chinese Materia Medica

Nanjing University of Chinese Medicine

Zhongshan Institute for Drug Discovery, The Institutes of Drug Discovery and Development

Chinese Academy of Sciences

Funding

Natural Science Foundation of Shanghai Municipality · Guangdong Provincial Department of Science and Technology · Zhongshan Science and Technology Bureau · National Key Research and Development Program of China · Chinese Academy of Sciences

References (42)

Show source-provided references
1. 10.1016/j.cell.2024.04.00210.1016/j.cell.2024.04.002 ↗
2. 10.1080/15384101.2018.144430510.1080/15384101.2018.1444305 ↗
3. 10.1038/s41392-023-01452-110.1038/s41392-023-01452-1 ↗
4. 10.1016/j.ccell.2022.01.00110.1016/j.ccell.2022.01.001 ↗
5. 10.1126/sciadv.adg269710.1126/sciadv.adg2697 ↗
6. 10.1016/j.phymed.2021.15380510.1016/j.phymed.2021.153805 ↗
7. 10.1021/acs.nanolett.9b0002110.1021/acs.nanolett.9b00021 ↗
8. 10.1136/jitc-2020-00165710.1136/jitc-2020-001657 ↗
9. 10.1186/s13046-021-02043-010.1186/s13046-021-02043-0 ↗
10. 10.1021/accountsmr.4c0036210.1021/accountsmr.4c00362 ↗
11. 10.1039/D0NH00605J10.1039/D0NH00605J ↗
12. 10.1016/j.jconrel.2023.12.05210.1016/j.jconrel.2023.12.052 ↗
13. 10.1007/s12274-021-3976-910.1007/s12274-021-3976-9 ↗
14. 10.1016/j.jconrel.2021.05.04010.1016/j.jconrel.2021.05.040 ↗
15. 10.1002/adma.20240497110.1002/adma.202404971 ↗
16. 10.1021/acsami.5c0510410.1021/acsami.5c05104 ↗
17. 10.1016/j.msec.2020.11183510.1016/j.msec.2020.111835 ↗
18. 10.1186/s12951-023-02224-310.1186/s12951-023-02224-3 ↗
19. 10.1002/advs.20240338810.1002/advs.202403388 ↗
20. 10.1002/smll.20220535410.1002/smll.202205354 ↗
21. 10.1002/advs.20220769310.1002/advs.202207693 ↗
22. 10.1016/j.phymed.2023.15470110.1016/j.phymed.2023.154701 ↗
23. 10.7150/ijbs.3695510.7150/ijbs.36955 ↗
24. 10.7150/thno.8165010.7150/thno.81650 ↗
25. 10.1002/adhm.20210192610.1002/adhm.202101926 ↗
26. 10.1016/j.biomaterials.2021.12111010.1016/j.biomaterials.2021.121110 ↗
27. 10.1002/smll.20231030010.1002/smll.202310300 ↗
28. 10.1021/acsmaterialslett.4c0050410.1021/acsmaterialslett.4c00504 ↗
29. 10.1016/j.jconrel.2020.10.05210.1016/j.jconrel.2020.10.052 ↗
30. 10.1016/j.semcancer.2022.09.00710.1016/j.semcancer.2022.09.007 ↗
31. 10.1002/cac2.1241610.1002/cac2.12416 ↗
32. 10.1021/acsnano.1c1157810.1021/acsnano.1c11578 ↗
33. 10.1038/s12276-020-00500-y10.1038/s12276-020-00500-y ↗
34. 10.1038/s41590-023-01738-010.1038/s41590-023-01738-0 ↗
35. 10.1016/j.immuni.2024.01.01910.1016/j.immuni.2024.01.019 ↗
36. 10.1001/jamaoncol.2023.509810.1001/jamaoncol.2023.5098 ↗
37. 10.1371/journal.pmed.100362010.1371/journal.pmed.1003620 ↗
38. 10.1002/adma.20230708110.1002/adma.202307081 ↗
39. 10.1016/j.biomaterials.2023.12218910.1016/j.biomaterials.2023.122189 ↗
40. 10.1016/j.carbpol.2018.09.06510.1016/j.carbpol.2018.09.065 ↗
41. 10.1016/j.jcis.2019.12.09610.1016/j.jcis.2019.12.096 ↗
42. 10.1136/jitc-2022-00561010.1136/jitc-2022-005610 ↗